Stabil idiyopatik pulmoner fibrozde hastalik şiddeti ve prognostik belirteçler ile matriks metallaproteinaz düzeyleri arasindaki ilişki

Year 2022, Volume: 47 Issue: 3, 1273 - 1280, 30.09.2022

Oya Baydar Toprak Ezgi Özyılmaz Yasemin Saygideger Efraim Güzel

https://doi.org/10.17826/cumj.1137742

Abstract

Amaç: Biyobelirteçler, son zamanlarda idiyopatik pulmoner fibrozis (İPF) olası tanısında prognostik göstergeler olarak kapsamlı bir şekilde değerlendirilmektedir. Yaygın IPF klinik uygulamasında dolaşımdaki biyobelirteçlerin değerini belirleyebilmek için bu çalışma, stabil idiyopatik pulmoner fibrozlu hastalarda hastalık şiddeti, prognostik göstergeler ve serum matriks metalloproteinaz arasındaki bağlantıya ilişkin sonuçlar çıkarmayı amaçlamaktadır.
Gereç ve Yöntem: Çalışma, multidisipliner bir yaklaşımla doğrulanmış İPF tanısı olan 22 kişiden oluşuyordu. Sosyodemografik detaylar, klinik ve radyolojik semptomlar, solunum fonksiyon testleri ve GAP skoru kaydedildi. Serum MMP konsantrasyonları ELISA yöntemiyle ölçülmüştür.
Bulgular: Matriks Metalloproteinaz (MMP) 2, MMP 7, MMP 9 ve MMP13 ile GAP indeksi ve solunum fonksiyon testleri veya hastalık şiddeti arasında istatistiksel olarak anlamlı bir ilişki yoktur. GAP skoru ağır hastalığı olanlarda evre 3'te, orta hastalığı olanlarda evre 2'de, hafif hastalığı olanlarda evre 1'de daha yüksek bulundu.
Sonuç: MMP ile İPF prognostik belirteçleri, solunum fonksiyon testleri ve hastalık şiddeti arasındaki ilişki bu incelemede görülmemesine rağmen literatürde tutarlı bulgular mevcuttur. Ancak, son teknoloji bir tedavi stratejisine kapı açabilecekleri için, bu göstergeler daha geniş serilerde ileriye dönük olarak araştırılmalıdır.

Keywords

idiopatik pulmoner fibrozis, matrix metalloproteinaz, gap, ciddiyet, biyomarker

Supporting Institution

yoktur

Thanks

yoktur

Relationship between disease severity and prognostic indicators and matrix metallaproteinase in patients with stable idiopatic pulmonary fibrosis

Abstract

Purpose: Blood-derived biomarkers have been extensively considered as possible prognostic indicators in idiopathic pulmonary fibrosis (IPF) recently. In order to assess the value of circulating biomarkers in common IPF clinical practice, the study intends to draw conclusions regarding the link between disease severity, prognostic indicators, and serum matrix metalloproteinase in patients with stable idiopathic pulmonary fibrosis.
Materials and Methods: The study comprised 22 people with an IPF diagnosis that had been verified by a multidisciplinary approach. The sociodemographic details, clinical and radiologic symptoms, pulmonary function tests and the Gender-Age-Physiology (GAP) score were noted. ELISA has been used to research serum MMP concentrations.
Results: There is no statistically significant correlation between the Matrix Metalloproteinase (MMP) 2, MMP 7, MMP 9, and MMP13 and the GAP index and, pulmonary function tests, or disease severity. GAP score was found to be higher in stage 3 in patients with severe disease, in stage 2 in patients with moderate disease, and in stage 1 in patients with mild disease.
Conclusion: There are consistent findings in the literature, despite the fact that the association between MMP and IPF prognostic markers, pulmonary function tests, and disease severity could not be seen in this investigation. However, because they could open the door to a cutting-edge treatment strategy, these indicators should be investigated prospectively in larger series.

Keywords

idiopathic pulmonary fibrosis, matrix metalloproteinases, gap, severity, biomarkers

References

• 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. PMID: 21471066; PMCID: PMC5450933.
• 2. Devaraj A. Imaging: how to recognise idiopathic pulmonary fibrosis. Eur Respir Rev. 2014;23:215-9. PMID: 24881075.
• 3. European Commission. Radiation Protection 118: Referral Guidelines for Imaging. Luxembourg: Office for Official Publications of the European Communities; 2001. Available from: https://health.gov.mt/ en/forms/Documents/radiation_protection.pdf. Accessed August 1, 2017.
• 4. Thannickal VJ, Murthy M, Balch WE, Chandel NS, Meiners S, Eickelberg O et al. Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med. 2015;191:261-9. PMID: 25590812; PMCID: PMC4351581.
• 5. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med. 2014;189:1161-72. PMID: 24641682.
• 6. Mahalanobish S, Saha S, Dutta S, Sil PC. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis. Pharmacol Res. 2020;152:104591. PMID: 31837390.
• 7. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697-722. PMID: 18195376..
• 8. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138-153. PMID: 29154106.
• 9. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al.American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:44-e68. PMID: 30168753.
• 10. Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J. 2011;80:84-90. PMID: 22347750; PMCID: PMC3229853.
• 11. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019 15;200:e70-e88. PMID: 31613151; PMCID: PMC6794117.
• 12. Liu YM, Nepali K, Liou JP. Idiopathic pulmonary fibrosis: Current status, recent progress, and emerging targets. J Med Chem. 2017;60:527-553.. PMID: 28122457.
• 13. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac Soc. 2015;12:16-20. PMID: 25830828; PMCID: PMC4430974.
• 14. Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol. 2018;68-69:404-421. PMID: 29408012.
• 15. Liu H, Wu X, Gan C, Wang L, Wang G, Yue L et al. A novel multikinase inhibitor SKLB-YTH-60 ameliorates inflammation and fibrosis in bleomycin-induced lung fibrosis mouse models. Cell Prolif. 2021;54:13081. PMID: 34121240; PMCID: PMC8249783.
• 16. Upagupta C, Shimbori C, Alsilmi R, Kolb M. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev. 2018;27:180033. PMID: 29950306.
• 17. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017 20;3:17074. PMID: 29052582.
• 18. Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T, Maisi P et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J. 2002;20:1220-7. PMID: 12449177.
• 19. García-de-Alba C, Becerril C, Ruiz V, González Y, Reyes S, García-Alvarez J et al. Expression of matrix metalloproteases by fibrocytes: possible role in migration and homing. Am J Respir Crit Care Med. 2010;182:1144-52. PMID: 20622038.
• 20. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J. 2011;38:1461-7. PMID: 21700608.
• 21. Shi Y, Xu L, Tao M, Fang L, Lu J, Gu H et al. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia. Am J Physiol Renal Physiol. 2019;316:F488-F505. PMID: 30566000; PMCID: PMC6734054.
• 22. Sen AI, Shiomi T, Okada Y, D'Armiento JM. Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury. Exp Lung Res. 2010;36:615-24. PMID: 20860538; PMCID: PMC3286187.
• 23. Majewski S, Szewczyk K, Żal A, Białas AJ, Miłkowska-Dymanowska J, Piotrowski WJ. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study. J Clin Med. 2021;10:3864. PMID: 34501312; PMCID: PMC8432145.
• 24. Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. 2021 29;59:2101612. PMID: 34588192; PMCID: PMC9202487.
• 25. Tzouvelekis A, Herazo-Maya JD, Slade M, Chu JH, Deiuliis G, Ryu C et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2017;22:486-493. PMID: 27761978; PMCID: PMC5352520.
• 26. Bruzova M, Pavlova M, Matej R, Sterclova M, Vasakova M. Interstitial score and concentrations of IL-4Rα, PAR-2, and MMP-7 in bronchoalveolar lavage fluid could be useful markers for distinguishing idiopathic interstitial pneumonias. Diagnostics. 2021;11:693. PMID: 33924683; PMCID: PMC8070528.
• 27. Määttä M, Laurila HP, Holopainen S, Aaltonen K, Lilja-Maula L, Viitanen S et al. Matrix metalloproteinase-2, -7, and -9 activities in dogs with idiopathic pulmonary fibrosis compared to healthy dogs and dogs with other respiratory diseases. J Vet Intern Med. 2021;35:462-471. PMID: 33274549; PMCID: PMC7848316.
• 28. Abd-Elaziz K, Jesenak M, Vasakova M, Diamant Z. Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases. Curr Opin Pulm Med. 2021;27:54-60. PMID: 33065600.